22 is the total number of securities Polaris Venture Management Co. V, L.L.C. has owned. The longest Polaris Venture Management Co. V, L.L.C. has owned a single stock is 30 quarters.
| Period | Weighting | Quarter | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Ticker | Name | Longest | Shortest | Min. | Avg. | Max. | First | Latest | ↓ Count |
| FATE | Fate Therapeutics, Inc. | 30 | 30 | 4.25% | 20.34% | 79.24% | Q1 2014 | Q2 2021 | 30 |
| LIFE | Atyr Pharma Inc. | 26 | 26 | 0.26% | 4.30% | 15.10% | Q2 2015 | Q3 2021 | 26 |
| TRVN | Trevena, Inc. | 22 | 22 | 0.94% | 10.82% | 24.89% | Q1 2014 | Q2 2019 | 22 |
| GNCA | Genocea Biosciences, Inc. | 21 | 21 | 0.60% | 9.84% | 32.52% | Q1 2014 | Q1 2019 | 21 |
| SELB | Selecta Biosciences, Inc. | 20 | 20 | 2.76% | 15.57% | 39.54% | Q2 2016 | Q1 2021 | 20 |
| TTOO | T2 Biosystems, Inc. | 20 | 20 | 2.43% | 12.85% | 36.14% | Q3 2014 | Q2 2019 | 20 |
| DARE | Dare Bioscience, Inc. | 17 | 17 | 0.14% | 0.61% | 3.87% | Q3 2017 | Q3 2021 | 17 |
| PULM | Pulmatrix, Inc. | 16 | 16 | 0.39% | 6.36% | 15.45% | Q2 2015 | Q1 2019 | 16 |
| CERU | Cerulean Pharma Inc | 13 | 13 | 2.76% | 9.09% | 16.18% | Q2 2014 | Q2 2017 | 13 |
| KALA | Kala Pharmaceuticals, ... | 11 | 11 | 1.52% | 13.44% | 37.13% | Q3 2017 | Q1 2020 | 11 |
| XFOR | x4 Pharmaceuticals Inc. | 11 | 11 | 2.25% | 3.87% | 11.70% | Q1 2019 | Q3 2021 | 11 |
| BINDQ | Bind Therapeutics, Inc. | 10 | 10 | 0.85% | 8.86% | 21.68% | Q1 2014 | Q2 2016 | 10 |
| STIM | Neuronetics, Inc. | 10 | 10 | 1.10% | 7.32% | 17.04% | Q2 2018 | Q3 2020 | 10 |
| GNCA | Genocea Biosciences, Inc. | 10 | 10 | 0.37% | 0.79% | 2.69% | Q2 2019 | Q3 2021 | 10 |
| PULM | Pulmatrix, Inc. | 10 | 10 | 0.17% | 0.60% | 2.04% | Q2 2019 | Q3 2021 | 10 |
| OCUL | Ocular Therapeutix, Inc. | 9 | 9 | 3.81% | 11.78% | 38.08% | Q1 2015 | Q1 2017 | 9 |
| CDLX | Cardlytics, Inc. | 8 | 8 | 9.14% | 29.38% | 46.48% | Q1 2018 | Q4 2019 | 8 |
| LYRA | Lyra Therapeutics, Inc. | 6 | 6 | 9.72% | 24.73% | 71.28% | Q2 2020 | Q3 2021 | 6 |
| ASNS | Arsanis, Inc. | 5 | 5 | 1.52% | 11.05% | 24.39% | Q4 2017 | Q4 2018 | 5 |
| Phreesia, Inc. | 4 | 4 | 48.73% | 55.34% | 62.28% | Q3 2019 | Q2 2020 | 4 | |
| TWTR | Twitter, Inc. | 1 | 1 | 2.86% | 2.86% | 2.86% | Q1 2014 | Q1 2014 | 1 |
| TRLA | Trulia, Inc. | 1 | 1 | 0.03% | 0.03% | 0.03% | Q1 2014 | Q1 2014 | 1 |
Download | |||||||||
The securities at the top of the list , including Fate Therapeutics, Inc., Atyr Pharma Inc., and Trevena, Inc., are the highest-conviction holdings of Polaris Venture Management Co. V, L.L.C..
The conviction is calculated by counting the number of quarters a security has been reported by Polaris Venture Management Co. V, L.L.C.. The higher the number, the higher the conviction and longer the holding period.
This page lists all the securities that Polaris Venture Management Co. V, L.L.C. owns currently or has owned in the past.